Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinsuke Iida

Showing results (31-40 of 328) with videos related to

Pageof 33
Sort By:
Blood Cancer Journal|July 5, 2023
Correction: Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapyNoopur Raje, María-Victoria Mateos, Shinsuke Iida, et al.
Experimental Hematology|July 31, 2022
Lineage- and Stage-Specific Oncogenicity of IRF4Stella Amanda, Tze King Tan, Shinsuke Iida, et al.
Internal Medicine (Tokyo, Japan)|February 18, 2014
Amelanotic malignant melanoma of unknown primary origin metastasizing to the bone marrow: a case report and review of the literatureTomotaka Suzuki, Shigeru Kusumoto, Shinsuke Iida, et al.
Ejhaem|January 16, 2026
Whole Genome and Single-Cell RNA Sequencing Reveals Clonal Evolution and Heterogeneity of Secondary Plasma Cell Leukemia: A Case ReportTomotaka Suzuki, Rui Yokomori, Takaomi Sanda, et al.
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine|August 26, 2011
[Discussion meeting on lymphoid malignancies: advances in diagnosis and treatment]Tomomitsu Hotta, Takuya Yamashita, Akira Fujita, et al.
Journal of Medical Economics|April 3, 2023
Evaluating process utilities for the treatment burden of chemotherapy in multiple myeloma in Japan: a time trade-off valuation studyTadao Ishida, Mayuko Nakakoji, Tatsunori Murata, et al.
International Journal of Hematology|July 28, 2016
Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myelomaShinsuke Iida, Kensei Tobinai, Masafumi Taniwaki, et al.
International Journal of Hematology|September 11, 2020
Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myelomaHirohiko Shibayama, Morio Matsumoto, Hiroshi Kosugi, et al.
International Journal of Hematology|December 27, 2024
Isatuximab plus pomalidomide and dexamethasone in frail individuals with relapsed/refractory multiple myeloma in JapanNami Tagami, Michihiro Uchiyama, Kenshi Suzuki, et al.
Plos One|April 6, 2023
Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims databaseHiroshi Handa, Tadao Ishida, Shuji Ozaki, et al.
Pageof 33

Showing results (31-40 of 328) with videos related to

Sort By:
Pageof 33
Blood Cancer Journal|July 5, 2023
Correction: Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapyNoopur Raje, María-Victoria Mateos, Shinsuke Iida, et al.
Experimental Hematology|July 31, 2022
Lineage- and Stage-Specific Oncogenicity of IRF4Stella Amanda, Tze King Tan, Shinsuke Iida, et al.
Internal Medicine (Tokyo, Japan)|February 18, 2014
Amelanotic malignant melanoma of unknown primary origin metastasizing to the bone marrow: a case report and review of the literatureTomotaka Suzuki, Shigeru Kusumoto, Shinsuke Iida, et al.
Ejhaem|January 16, 2026
Whole Genome and Single-Cell RNA Sequencing Reveals Clonal Evolution and Heterogeneity of Secondary Plasma Cell Leukemia: A Case ReportTomotaka Suzuki, Rui Yokomori, Takaomi Sanda, et al.
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine|August 26, 2011
[Discussion meeting on lymphoid malignancies: advances in diagnosis and treatment]Tomomitsu Hotta, Takuya Yamashita, Akira Fujita, et al.
Journal of Medical Economics|April 3, 2023
Evaluating process utilities for the treatment burden of chemotherapy in multiple myeloma in Japan: a time trade-off valuation studyTadao Ishida, Mayuko Nakakoji, Tatsunori Murata, et al.
International Journal of Hematology|July 28, 2016
Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myelomaShinsuke Iida, Kensei Tobinai, Masafumi Taniwaki, et al.
International Journal of Hematology|September 11, 2020
Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myelomaHirohiko Shibayama, Morio Matsumoto, Hiroshi Kosugi, et al.
International Journal of Hematology|December 27, 2024
Isatuximab plus pomalidomide and dexamethasone in frail individuals with relapsed/refractory multiple myeloma in JapanNami Tagami, Michihiro Uchiyama, Kenshi Suzuki, et al.
Plos One|April 6, 2023
Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims databaseHiroshi Handa, Tadao Ishida, Shuji Ozaki, et al.
Pageof 33